Tebentafusp in first-line melanoma trials: An outperforming outlier-Reference-Cited by-同舟云学术

Tebentafusp in first-line melanoma trials: An outperforming outlier

Published:2022-06 Issue: Volume:20 Page:101408
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Olivier Timothée^ORCID,Prasad Vinay

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference13 articles.

1. Tebentafusp, A TCR/Anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma;Middleton;Clin. Cancer Res.,2020

2. 64MO-A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM);Sacco;Ann. Oncol.,2020

3. Overall survival benefit with tebentafusp in metastatic uveal melanoma;Nathan;N. Engl. J. Med.,2021

4. Monoclonal TCR-redirected tumor cell killing;Liddy;Nat. Med.,2012

5. ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells;Bossi;Cancer Immunol. Immunother.,2014

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic and predictive biomarkers in melanoma;Pathology;2023-12

2. Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp;European Journal of Cancer;2023-09

3. Cost-effectiveness analysis of an orphan drug tebentafusp in patients with metastatic uveal melanoma and a call for value-based pricing;Melanoma Research;2023-08-25

4. Role of immune checkpoint inhibitors in metastatic uveal melanoma: a single-center retrospective cohort study;Acta Oncologica;2023-05-04

5. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022;Naunyn-Schmiedeberg's Archives of Pharmacology;2023-03-23